BTIG analyst Mark Massaro maintains $Castle Biosciences (CSTL.US)$ with a buy rating, and adjusts the target price from $40 to $45.
According to TipRanks data, the analyst has a success rate of 30.8% and a total average return of -9.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Castle Biosciences (CSTL.US)$'s main analysts recently are as follows:
Castle Biosciences has reported yet another robust quarter, surpassing expectations and achieving GAAP profit for the second sequential quarter. The company's risk/reward profile remains favorable. There appears to be a strong possibility that reimbursement payments for the company's squamous cell carcinoma test could be extended past the fourth quarter. This is supported by the fact that the company has been receiving payments for over two and a half years and has effectively accumulated additional evidence and data that may justify the ongoing coverage under Medicare reimbursement.
Castle Biosciences exhibited a solid third quarter, achieving revenue expectations and demonstrating promising operational expenditure leverage. While overall volumes increased, dermatology volumes fell short of estimates attributable to seasonal patterns, yet the TissueCypher product continued to show impressive momentum.
The determination of coverage for the SCC test will continue to be a focal point, yet it is observed that the company is advancing its volume for other tests, including growth in IDgenetix and TissueCypher. These tests have played a significant role in the robust quarterly results and have been a factor in the enhanced revenue guidance.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
BTIG分析師Mark Massaro維持$Castle Biosciences (CSTL.US)$買入評級，並將目標價從40美元上調至45美元。
根據TipRanks數據顯示，該分析師近一年總勝率為30.8%，總平均回報率為-9.3%。
此外，綜合報道，$Castle Biosciences (CSTL.US)$近期主要分析師觀點如下：
castle biosciences又報告了強勁的季度，超出預期並連續第二個季度實現了GAAP盈利。該公司的風險/回報概況仍然有利。有很大可能性公司鱗狀細胞癌檢測的報銷款項會延長至第四季度之後，這得到了支撐，因爲公司已經連續兩年半收到了付款，並已有效地積累了可能證明符合在醫療保健金利益方案下繼續支付的額外證據和數據。
castle biosciences展示了強勁的第三季度，實現了營業收入的預期，並展現出具有潛力的運營支出槓桿作用。儘管總體成交量有所增加，皮膚科成交量未達到預期，歸因於季節性模式，但TissueCypher產品仍然表現出令人印象深刻的增長動力。
鱗狀細胞癌檢測的報銷範圍決定將繼續是重點，但觀察到公司正在推進其他檢測的成交量，包括IDgenetix和TissueCypher的增長。這些檢測在強勁的季度業績中發揮了重要作用，併成爲增強營業收入指引的因素。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
